Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
A phase IV, randomized, double-blind, single center pilot study in subjects with type 2
diabetes poorly controlled with metformin therapy will be randomized to receive, on top of
metformin: saxagliptin (5 mg/day) and dapagliflozin (10 mg/day) (Group 1);saxagliptin (5
mg/day) and placebo (Group 2); dapagliflozin (10 mg/day) and placebo (Group 3) for 4 weeks.